|
|
|
|
|
|
|
|
open access
Ovarian cancer accounts for only 3% of
all cancers in women, but it causes more deaths than any other
gynecologic cancer. Treatment with chemotherapy and cytoreductive
surgery shows a good response to the therapy. However, in a large
proportion of the patients the tumor grows back within a few years.
Cancer stem cells, that are less responsive to these treatments, are
blamed for this recurrence of disease. Immune therapy either cellular or
humoral is a novel concept to treat cancer. It is based on the notice
that immune cells invade the tumor. However, the tumor invest heavily to
escape from immune elimination by recruiting several immune suppressive
mechanisms. These processes are normally in place to limit excessive
immune activation and prevent autoimmune phenomena. Here, we discuss
current knowledge about the immune (suppressive) status in ovarian
cancer. Moreover, we discuss the immunological targets of ovarian cancer
stem cells.....
Core tip: Ovarian cancer harbors, at a low
frequency, cancer stem cells. Those cancer stem cells express stem cell
specific antigens. Natural immunity against those antigens exists but is
hampered by the suppressive microenvironment that the tumor creates.
Erasing this suppressive microenvironment will make immunological
elimination of those cancer stem cells is an attractive treatment
option.
|
|
|
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.